// App-Quantinova.ai

TPS630 : SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).

Researchers

Presenter

  • Hope S. Rugo

Principal Investigators

  • Mark D. Pegram

  • William John Gradishar

  • Javier Cortes

  • Giuseppe Curigliano

  • Jon M. Wigginton

  • Robert Joseph Lechleider

  • Fatima Cardoso

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • Stanford School of Medicine, Stanford, CA

  • Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Istituto Europeo di Oncologia, Milano, Italy

  • MacroGenics, Inc., Rockville, MD

  • Champalimaud Cancer Centre, Lisbon, Portugal

Locations

  • United States

  • Spain

  • Italy

  • Portugal

Companies

  • MacroGenics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Brain metastasis

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine

  • margetuximab

  • Gemcitabine

  • Trastuzumab

  • Vinorelbine

  • Eribulin

Outcome

  • N/A

Study Design

  • Randomized

  • Prospective

Phase

  • III

Study Id's

  • NCT02492711

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved